- Home
- MMV vs SYBX Comparison
MMV vs SYBX Comparison
Compare MMV & SYBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MMV
- SYBX
- Stock Information
- Founded
- MMV 2015
- SYBX N/A
- Country
- MMV China
- SYBX United States
- Employees
- MMV N/A
- SYBX N/A
- Industry
- MMV Blank Checks
- SYBX Biotechnology: Pharmaceutical Preparations
- Sector
- MMV Finance
- SYBX Health Care
- Exchange
- MMV Nasdaq
- SYBX Nasdaq
- Market Cap
- MMV 18.8M
- SYBX 17.5M
- IPO Year
- MMV N/A
- SYBX N/A
- Fundamental
- Price
- MMV $0.42
- SYBX $1.43
- Analyst Decision
- MMV
- SYBX Buy
- Analyst Count
- MMV 0
- SYBX 4
- Target Price
- MMV N/A
- SYBX $15.50
- AVG Volume (30 Days)
- MMV 135.4K
- SYBX 10.2K
- Earning Date
- MMV 01-01-0001
- SYBX 11-07-2024
- Dividend Yield
- MMV N/A
- SYBX N/A
- EPS Growth
- MMV N/A
- SYBX N/A
- EPS
- MMV N/A
- SYBX N/A
- Revenue
- MMV $9,008,244.00
- SYBX $3,170,000.00
- Revenue This Year
- MMV N/A
- SYBX N/A
- Revenue Next Year
- MMV N/A
- SYBX N/A
- P/E Ratio
- MMV N/A
- SYBX N/A
- Revenue Growth
- MMV N/A
- SYBX 219.23
- 52 Week Low
- MMV $0.38
- SYBX $1.22
- 52 Week High
- MMV $2.05
- SYBX $5.12
- Technical
- Relative Strength Index (RSI)
- MMV 38.40
- SYBX 45.51
- Support Level
- MMV $0.38
- SYBX $1.39
- Resistance Level
- MMV $0.46
- SYBX $1.49
- Average True Range (ATR)
- MMV 0.05
- SYBX 0.06
- MACD
- MMV -0.01
- SYBX -0.00
- Stochastic Oscillator
- MMV 21.85
- SYBX 23.53
About MMV MultiMetaVerse Holdings Limited
MultiMetaVerse Holdings Ltd is an animation and entertainment company. It is devoted to establishing an open community for its global users comprised of animation viewers, game players, and content creators and to providing high-quality and immersive entertainment experiences by way of original content, user-generated content, and professional user-generated content.
About SYBX Synlogic Inc.
Synlogic Inc is a biopharmaceutical company focuses on rare metabolic disorders, with a lead program in phenylketonuria (PKU) and homocystinuria (HCU). The company's pipeline includes therapeutics for enteric hyperoxaluria, gout, and cystinuria. Using a proprietary approach, the company engineer GI-restricted, oral medicines from well-characterized probiotics. These drug candidates target specific biological pathways, leveraging Escherichia coli Nissle 1917 for consistency and safety. Engineered to be non-colonizing and reversible, the company offer oral administration, simplifying shipping and storage. The company operates in one segment-discovery and development of Synthetic Biotics-pioneering transformative treatments for serious diseases.